Nakatoh, Shinichi http://orcid.org/0000-0001-7928-0014
Fujimori, Kenji
Tamaki, Junko
Okimoto, Nobukazu
Ogawa, Sumito
Iki, Masayuki
Article History
Received: 2 April 2020
Accepted: 29 November 2020
First Online: 5 January 2021
Compliance with ethical standards
:
: S. Nakatoh has received lecture fees from Asahi-Kasei Pharmaceutical Co., Ltd.; Pfizer Japan Inc.; Amgen Astellas BioPharma K.K.; Astellas Pharma Inc.; Daiichi-Sankyo Co. Ltd.; and Eli Lilly Japan K.K. N. Okimoto has received consulting fees from Asahi-Kasei Pharmaceutical Co., Ltd and Teijin Pharma Ltd. N. Okimoto has received payments for lectures, including speakers’ bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd.; Amgen Astellas BioPharma K.K.; Astellas Pharma Inc.; Chugai Pharmaceutical Co.; Daiichi-Sankyo Co. Ltd.; Eisai Co., Ltd.; Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Corp.; Ono Pharmaceutical Co.; Pfizer Japan Inc.; and Teijin Pharma Ltd. The other authors have no conflicts of interest.
: This study was conducted according to the principles of the Declaration of Helsinki and approved by the institutional review board of the Asahi General Hospital (IRB No. 19-02) and the ethics committee of Tohoku University as “Examination of drug treatment compliance in osteoporosis using an electronic claim database” (2018-1-868). This study was a part of the “medical/nursing care information database development project,” in which the National Health Insurance Federation was instructed by the Hokkaido Government to construct the database at Tohoku University. The claim data, which were collected by KF, were provided by the governor with the approval by all municipal governments after anonymization in the National Health Insurance Federation.
: The data in this study were completely anonymous; thus, informed consent was not required.